Key clinical point: Minor surgery in patients taking emicizumab for hemophilia A may not require prophylactic coagulation factor therapy.
Major finding: Among hemophilia A patients receiving emicizumab and undergoing minor surgery, 90.8% did not experience a postoperative bleed requiring treatment.
Study details: Analysis of data from four HAVEN studies and involving 399 patients with hemophilia A.
Disclosures: The study was funded by F. Hoffman-La Roche and Chugai Pharmaceutical. Dr. Santagostino reported consultancies and speakers bureau engagements with the pharmaceutical sector.
Santagostino E et al. 2019 ISTH Congress, Abstract OC 60.1.